Cormedix Inc (CRMD) 3.27 $CRMD
CorMedix (CRMD) Shows Strength: Stock Moves Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:51AM CST
CorMedix, Inc. (CRMD) was a big mover last session, as the company saw its shares rise almost 6% on the day.
CRMD: 3.27 (+0.02), AFFX: 11.45 (+0.02)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:37PM CST
CRMD: 3.27 (+0.02), TTWO: 28.40 (+0.96), MYGN: 34.03 (+0.40), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), MXL: 8.37 (+0.09), WTW: 18.16 (+0.33), DWTI: 95.90 (-7.40), PLNR: 6.63 (-0.07), ENTR: 2.92 (unch)
CorMedix (CRMD) Looks Good: Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
CorMedix (CRMD) was a big mover last session, with shares rising over 9% on the day.
CRMD: 3.27 (+0.02), RGDO: 1.17 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), SILC: 46.99 (+0.90), GNCA: 8.93 (-0.07), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), LRN: 16.56 (-0.06), SR: 1.25 (+0.08), DSKY: 11.99 (+0.14), GENE: 8.04 (+1.90), SMLR: 4.54 (+0.20), PFMT: 6.02 (-0.02), QCOM: 70.88 (+0.49), PSTR: 4.63 (+0.14), ENTL: 21.99 (+0.56), ATTU: 9.93 (+0.05), CTP: 6.53 (+0.13), LENS: 6.00 (-0.67), RCON: 2.11 (+0.15)
CorMedix up on QIDP designation
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 9:37AM CST
CRMD: 3.27 (+0.02)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.'s Lead Product Candidate in the U.S.
PR Newswire - Thu Jan 29, 8:00AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated the company's lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening.
CRMD: 3.27 (+0.02)
CorMedix accuses German firm of foul play with its Neutrolin competitor
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 6:34AM CST
CRMD: 3.27 (+0.02)
CorMedix awarded US FDA's fast track designation for Neutrolin
M2 - Fri Jan 16, 7:31AM CST
Specialist pharmaceutical company CorMedix (NYSE MKT:CRMD) disclosed on Thursday the US Food and Drug Administration's (FDA) fast track designation of its lead product candidate, Neutrolin Catheter Lock Solution under the Food and Drug Administration Safety and Innovation Act (FDASIA).
CRMD: 3.27 (+0.02)
Neutrolin Fast Track'd
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 10:27AM CST
CRMD: 3.27 (+0.02)
CorMedix Inc. Receives Fast Track Designation for Neutrolin®
PR Newswire - Thu Jan 15, 9:34AM CST
CorMedix Inc. (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) granted its request for Fast Track designation of its lead product candidate, Neutrolin® Catheter Lock Solution, pursuant to the Food and Drug Administration Safety and Innovation Act (FDASIA). CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation.
CRMD: 3.27 (+0.02)
What's Buzzing on Street: New Research on CorMedix, American Apparel, Horizon, Nike and Amazon
PR Newswire - Mon Dec 29, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including CorMedix (NYSE MKT: CRMD), American Apparel (NYSE MKT: APP), Horizon (NASDAQ: HZNP), Nike (NYSE: NKE), and Amazon (NASDAQ: AMZN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CRMD: 3.27 (+0.02), AMZN: 381.83 (+4.66), APP: 0.92 (+0.04), NKE: 92.04 (+0.04), HZNP: 16.84 (-0.41)
CorMedix Update: Setting A New Standard For Catheter Care
Mark Kroenke - Seeking Alpha - Sun Dec 28, 6:07AM CST
Back in August, CorMedix (NYSEMKT: CRMD ) had a long to do list. In the last 4 months, the company has delivered on many promises: An IND for the pivotal Neutrolin study in the US was filed and accepted. The EU Neutrolin label was successfully...
CRMD: 3.27 (+0.02)
CorMedix reports first Middle East sales/distribution agreement for Neutrolin
M2 - Wed Dec 24, 5:22AM CST
Pharmaceutical company CorMedix (NYSE MKT:CRMD) disclosed on Tuesday the launch of its first Middle East sales/distribution agreement for lead product Neutrolin in Saudi Arabia.
CRMD: 3.27 (+0.02)
CorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution Agreement in the Kingdom of Saudi Arabia
PR Newswire - Tue Dec 23, 7:30AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia.
CRMD: 3.27 (+0.02)
CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin®
PR Newswire - Thu Dec 04, 8:22AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration (FDA) for designation of its lead product candidate, Neutrolin® Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act (FDASIA). Neutrolin contains taurolidine, which has been shown to be a potent anti-infective agent that is active against gram positive and gram negative bacteria, and also contains heparin to ensure patency of the catheter. Dr. Douglas Webb, an infectious disease expert and a member of the CorMedix Scientific Advisory Board, noted that "GAIN is intended to encourage development of new antibacterial and antifungal drugs to address serious and life-threatening infections. Neutrolin has shown antimicrobial activity against several of the qualifying pathogens that FDA has designated for GAIN and that are documented to be a serious threat to public health by causing blood-stream infections in hemodialysis patients, including Staphylococcus aureus, Pseudomonas species, and Enterococcus species."
CRMD: 3.27 (+0.02)
Neutrolin Label Expansion Approved in Germany
PR Newswire - Wed Dec 03, 1:09PM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the approval of a label expansion from the Hessian District President in Germany for its lead product Neutrolin®, a catheter lock solution.
CRMD: 3.27 (+0.02)
CorMedix's (CRMD) CEO Randy Milby on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 12:08PM CST
CRMD: 3.27 (+0.02)
CorMedix misses by $0.14
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 5:43PM CST
CRMD: 3.27 (+0.02)
CorMedix (CRMD) Shows Strength: Stock Moves Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:51AM CST
CorMedix, Inc. (CRMD) was a big mover last session, as the company saw its shares rise almost 6% on the day.
CRMD: 3.27 (+0.02), AFFX: 11.45 (+0.02)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:37PM CST
CRMD: 3.27 (+0.02), TTWO: 28.40 (+0.96), MYGN: 34.03 (+0.40), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), MXL: 8.37 (+0.09), WTW: 18.16 (+0.33), DWTI: 95.90 (-7.40), PLNR: 6.63 (-0.07), ENTR: 2.92 (unch)
CorMedix (CRMD) Looks Good: Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
CorMedix (CRMD) was a big mover last session, with shares rising over 9% on the day.
CRMD: 3.27 (+0.02), RGDO: 1.17 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:47AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), SILC: 46.99 (+0.90), GNCA: 8.93 (-0.07), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), LRN: 16.56 (-0.06), SR: 1.25 (+0.08), DSKY: 11.99 (+0.14), GENE: 8.04 (+1.90), SMLR: 4.54 (+0.20), PFMT: 6.02 (-0.02), QCOM: 70.88 (+0.49), PSTR: 4.63 (+0.14), ENTL: 21.99 (+0.56), ATTU: 9.93 (+0.05), CTP: 6.53 (+0.13), LENS: 6.00 (-0.67), RCON: 2.11 (+0.15)
CorMedix up on QIDP designation
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 9:37AM CST
CRMD: 3.27 (+0.02)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.'s Lead Product Candidate in the U.S.
PR Newswire - Thu Jan 29, 8:00AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated the company's lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening.
CRMD: 3.27 (+0.02)
CorMedix accuses German firm of foul play with its Neutrolin competitor
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 6:34AM CST
CRMD: 3.27 (+0.02)
CorMedix awarded US FDA's fast track designation for Neutrolin
M2 - Fri Jan 16, 7:31AM CST
Specialist pharmaceutical company CorMedix (NYSE MKT:CRMD) disclosed on Thursday the US Food and Drug Administration's (FDA) fast track designation of its lead product candidate, Neutrolin Catheter Lock Solution under the Food and Drug Administration Safety and Innovation Act (FDASIA).
CRMD: 3.27 (+0.02)
Neutrolin Fast Track'd
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 10:27AM CST
CRMD: 3.27 (+0.02)
CorMedix Inc. Receives Fast Track Designation for Neutrolin®
PR Newswire - Thu Jan 15, 9:34AM CST
CorMedix Inc. (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) granted its request for Fast Track designation of its lead product candidate, Neutrolin® Catheter Lock Solution, pursuant to the Food and Drug Administration Safety and Innovation Act (FDASIA). CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation.
CRMD: 3.27 (+0.02)
What's Buzzing on Street: New Research on CorMedix, American Apparel, Horizon, Nike and Amazon
PR Newswire - Mon Dec 29, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including CorMedix (NYSE MKT: CRMD), American Apparel (NYSE MKT: APP), Horizon (NASDAQ: HZNP), Nike (NYSE: NKE), and Amazon (NASDAQ: AMZN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CRMD: 3.27 (+0.02), AMZN: 381.83 (+4.66), APP: 0.92 (+0.04), NKE: 92.04 (+0.04), HZNP: 16.84 (-0.41)
CorMedix Update: Setting A New Standard For Catheter Care
Mark Kroenke - Seeking Alpha - Sun Dec 28, 6:07AM CST
Back in August, CorMedix (NYSEMKT: CRMD ) had a long to do list. In the last 4 months, the company has delivered on many promises: An IND for the pivotal Neutrolin study in the US was filed and accepted. The EU Neutrolin label was successfully...
CRMD: 3.27 (+0.02)
CorMedix reports first Middle East sales/distribution agreement for Neutrolin
M2 - Wed Dec 24, 5:22AM CST
Pharmaceutical company CorMedix (NYSE MKT:CRMD) disclosed on Tuesday the launch of its first Middle East sales/distribution agreement for lead product Neutrolin in Saudi Arabia.
CRMD: 3.27 (+0.02)
CorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution Agreement in the Kingdom of Saudi Arabia
PR Newswire - Tue Dec 23, 7:30AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia.
CRMD: 3.27 (+0.02)
CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin®
PR Newswire - Thu Dec 04, 8:22AM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration (FDA) for designation of its lead product candidate, Neutrolin® Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act (FDASIA). Neutrolin contains taurolidine, which has been shown to be a potent anti-infective agent that is active against gram positive and gram negative bacteria, and also contains heparin to ensure patency of the catheter. Dr. Douglas Webb, an infectious disease expert and a member of the CorMedix Scientific Advisory Board, noted that "GAIN is intended to encourage development of new antibacterial and antifungal drugs to address serious and life-threatening infections. Neutrolin has shown antimicrobial activity against several of the qualifying pathogens that FDA has designated for GAIN and that are documented to be a serious threat to public health by causing blood-stream infections in hemodialysis patients, including Staphylococcus aureus, Pseudomonas species, and Enterococcus species."
CRMD: 3.27 (+0.02)
Neutrolin Label Expansion Approved in Germany
PR Newswire - Wed Dec 03, 1:09PM CST
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the approval of a label expansion from the Hessian District President in Germany for its lead product Neutrolin®, a catheter lock solution.
CRMD: 3.27 (+0.02)
CorMedix's (CRMD) CEO Randy Milby on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 12:08PM CST
CRMD: 3.27 (+0.02)
CorMedix misses by $0.14
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 5:43PM CST
CRMD: 3.27 (+0.02)
